Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of the National Comprehensive Cancer Network : JNCCN|
|State||Published - May 1 2019|
ASJC Scopus subject areas